Novartis Strong phase 3 data boosts Novartis' Ibrance rival Ribociclib will compete against Pfizer's breast cancer blockbuster
News Pfizer fears rough ride with NICE over breast cancer drug Concerns over NICE's treatment of add-on therapies.
News Pfizer looks to confirm US licence for breast cancer pill Pfizer has filed late stage data with FDA.
News Women urged to look for "non-lump" breast cancer symptoms Patients with "non lump" symptoms more likely to delay doctor visit.
News NICE finally recommends Eisai breast cancer drug after rethi... New trial evidence and price cut convinces NICE in reassessment.
News Novartis' LEE011 on fast track to challenge Ibrance US regulator grants fast review for breast cancer drug.
News Relief for AZ as Truqap hits the spot in prostate cancer After a disappointing result with Truqap in triple-negative breast cancer, AstraZeneca chalks up a win in prostate cancer
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
